FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912513085> ?p ?o ?g. }

• W2912513085 endingPage "762" @default.
• W2912513085 startingPage "748" @default.
• W2912513085 abstract "An understanding of the mechanisms underlying acquired resistance to cetuximab is urgently needed to improve cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Here, we present a clinical observation that MET pathway activation constitutes the mechanism of acquired resistance to cetuximab in a patient with HNSCC. Specifically, RNA sequencing and mass spectrometry analysis of cetuximab‐sensitive (Cetux Sen ) and cetuximab‐resistant (Cetux Res ) tumors indicated MET amplification and overexpression in the Cetux Res tumor compared to the Cetux Sen lesion. Stimulation of MET in HNSCC cell lines was sufficient to reactivate the MAPK pathway and to confer resistance to cetuximab in vitro and in vivo . In addition to the direct role of MET in reactivation of the MAPK pathway, MET stimulation abrogates the well‐known cetuximab‐induced compensatory feedback loop of HER2/HER3 expression. Mechanistically, we showed that the overexpression of HER2 and HER3 following cetuximab treatment is mediated by the ETS homologous transcription factor (EHF), and is suppressed by MET/MAPK pathway activation. Collectively, our findings indicate that evaluation of MET and HER2/HER3 in response to cetuximab in HNSCC patients can provide the rationale of successive line of treatment." @default.
• W2912513085 created "2019-02-21" @default.
• W2912513085 creator A5002819777 @default.
• W2912513085 creator A5004300577 @default.
• W2912513085 creator A5014179206 @default.
• W2912513085 creator A5021400993 @default.
• W2912513085 creator A5021421185 @default.
• W2912513085 creator A5024957945 @default.
• W2912513085 creator A5027858056 @default.
• W2912513085 creator A5028992290 @default.
• W2912513085 creator A5040878299 @default.
• W2912513085 creator A5050029751 @default.
• W2912513085 creator A5072271778 @default.
• W2912513085 creator A5073065620 @default.
• W2912513085 creator A5073773875 @default.
• W2912513085 creator A5081303755 @default.
• W2912513085 creator A5086790489 @default.
• W2912513085 date "2019-02-11" @default.
• W2912513085 modified "2023-09-25" @default.
• W2912513085 title "MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer" @default.
• W2912513085 cites W1513520602 @default.
• W2912513085 cites W1914351667 @default.
• W2912513085 cites W1964550379 @default.
• W2912513085 cites W1967208836 @default.
• W2912513085 cites W1980497534 @default.
• W2912513085 cites W1990956554 @default.
• W2912513085 cites W1991233761 @default.
• W2912513085 cites W1997579117 @default.
• W2912513085 cites W1998971866 @default.
• W2912513085 cites W2004439203 @default.
• W2912513085 cites W2007513598 @default.
• W2912513085 cites W2007649418 @default.
• W2912513085 cites W2010601523 @default.
• W2912513085 cites W2012792646 @default.
• W2912513085 cites W2015307495 @default.
• W2912513085 cites W2017081079 @default.
• W2912513085 cites W2031016321 @default.
• W2912513085 cites W2039071845 @default.
• W2912513085 cites W2041919461 @default.
• W2912513085 cites W2055624262 @default.
• W2912513085 cites W2076138205 @default.
• W2912513085 cites W2090685720 @default.
• W2912513085 cites W2093036951 @default.
• W2912513085 cites W2094337993 @default.
• W2912513085 cites W2096362504 @default.
• W2912513085 cites W2097501495 @default.
• W2912513085 cites W2102354469 @default.
• W2912513085 cites W2108541764 @default.
• W2912513085 cites W2108718020 @default.
• W2912513085 cites W2112845420 @default.
• W2912513085 cites W2116731538 @default.
• W2912513085 cites W2118458295 @default.
• W2912513085 cites W2119540121 @default.
• W2912513085 cites W2119746400 @default.
• W2912513085 cites W2120588738 @default.
• W2912513085 cites W2125519805 @default.
• W2912513085 cites W2129907662 @default.
• W2912513085 cites W2130028615 @default.
• W2912513085 cites W2132551046 @default.
• W2912513085 cites W2136871952 @default.
• W2912513085 cites W2140407529 @default.
• W2912513085 cites W2141630197 @default.
• W2912513085 cites W2143902539 @default.
• W2912513085 cites W2149447281 @default.
• W2912513085 cites W2153534791 @default.
• W2912513085 cites W2155228605 @default.
• W2912513085 cites W2155384808 @default.
• W2912513085 cites W2155598934 @default.
• W2912513085 cites W2155933329 @default.
• W2912513085 cites W2156394972 @default.
• W2912513085 cites W2157824687 @default.
• W2912513085 cites W2158155247 @default.
• W2912513085 cites W2158508310 @default.
• W2912513085 cites W2161541244 @default.
• W2912513085 cites W2164837623 @default.
• W2912513085 cites W2168110569 @default.
• W2912513085 cites W2169456326 @default.
• W2912513085 cites W2171749007 @default.
• W2912513085 cites W2196002378 @default.
• W2912513085 cites W2281165738 @default.
• W2912513085 cites W2336559948 @default.
• W2912513085 cites W2460643788 @default.
• W2912513085 cites W2464944724 @default.
• W2912513085 cites W2512870827 @default.
• W2912513085 cites W2535069604 @default.
• W2912513085 cites W2542503890 @default.
• W2912513085 cites W2803252816 @default.
• W2912513085 cites W51995314 @default.
• W2912513085 doi "https://doi.org/10.1002/ijc.32170" @default.
• W2912513085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6554031" @default.
• W2912513085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30694565" @default.
• W2912513085 hasPublicationYear "2019" @default.
• W2912513085 type Work @default.
• W2912513085 sameAs 2912513085 @default.
• W2912513085 citedByCount "19" @default.
• W2912513085 countsByYear W29125130852019 @default.
• W2912513085 countsByYear W29125130852020 @default.
• W2912513085 countsByYear W29125130852021 @default.

• next